Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesSox antibodies in small cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival
Journal of Clinical Oncology, 08/14/09
Titulaer MJ et al. - In a trial to validate an enzyme-linked immunosorbent assay (ELISA) to assess the diagnostic value of serum antibodies in small-cell lung carcinoma (SCLC) and Lambert-Eaton myasthenic syndrome (LEMS), it was shown that SOX antibodies are specific serological markers for SCLC. This assay is suitable for high throughput screening, detecting 43% of SCLC. SOX antibodies have diagnostic value in discriminating SCLC-LEMS from nontumor LEMS, but have no relation to survival in pts with SCLC.
Methods- Recombinant SOX1, SOX2, SOX3, SOX21, HuC, HuD, or HelN1 proteins were used in an ELISA to titrate serum samples and validate the assay by western blot.
- 136 consecutive SCLC pts, 86 LEMS pts (43 with SCLC), 14 pts with SCLC and PNS (paraneoplastic cerebellar degeneration or Hu syndrome), 62 polyneuropathy pts, and 18 healthy controls were tested.
- ELISA was equally reliable as western blot.
- 43% of SCLC pts and 67% of SCLC-LEMS pts had antibodies to 1 of the SOX or Hu proteins.
- SOX antibodies had a sensitivity of 67% and a specificity of 95% to discriminate between LEMS with SCLC and nontumor LEMS.
- No difference in survival was observed between SOX-positive and SOX-negative SCLC pts.
Related Articles
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 Study
Journal of Clinical Oncology, 11/19/09
Relevance Score: 92%
Highly concordant coexpression of aromatase and estrogen receptor beta in non–small cell lung cancer
Human Pathology, 10/08/09
Relevance Score: 91%
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
Journal of Clinical Oncology, 11/12/09
Relevance Score: 90%
EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells
Molecular Cancer, 11/05/09
Relevance Score: 90%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 90%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Expression of HIF-1alpha and VEGF in colorectal cancer: Association with clinical outcomes and prognostic implications
BMC Cancer, 12/15/09
Polycomb group protein Bmi1 expression in colon cancers predicts the survival
Medical Oncology, 12/15/09
Decreased expression of KLF6 and its significance in gastric carcinoma
Medical Oncology, 12/15/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Lung cancer susceptibility among atomic bomb survivors in relation to CA repeat number polymorphism of epidermal growth factor receptor gene and radiation dose
Carcinogenesis, 12/15/09
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung
Clinical Cancer Research, 12/15/09
Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma
Clinical Cancer Research, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor